[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627667":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":55,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":32,"studyType":77,"phases":78,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":41,"whyStopped":32,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"University of California, Irvine","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A","ACTIVE_COMPARATOR","Unilateral, low dose",[13],"Biological: hNSC-01",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort B","Bilateral, low dose",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort C","Bilateral, mid-dose",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Cohort D","Bilateral, high dose",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"BIOLOGICAL","hNSC-01","neural stem cell therapy",[9,15,19,23],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"UCI Alpha Clinic","CONTACT","949-824-3990","alphaclinic@hs.uci.edu",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Irvine","California","92697","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-117.82311,33.66946,{"lat":51,"lon":50},[54],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"SPONSOR_INVESTIGATOR","Leslie Thompson","Bren Professor, Departments of Psychiatry and Human Behavior, Neurobiology and Behavior, and Biological Chemistry, Co-Director, UCI Sue & Bill Gross Research Center",[60,62],{"name":61,"class":6},"California Institute for Regenerative Medicine (CIRM)",{"name":5,"class":6},"100627667","phase-1-safety-and-tolerability-study-of-human-neural-stem-cells-for-huntingtons-disease-100627667",false,"NCT07451613","Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease","Phase 1B\u002F2A Study of the Safety and Tolerability of Human Neural Stem Cells for Huntington's Disease","REGEN4HD","Please note this may not be a complete list of eligibility criteria.\n\nInclusion Criteria:\n\n* Have decision-making capacity and be able to provide written informed consent.\n* Are between 18 to 65 years of age\n* Have genetically confirmed diagnosis of Huntington's Disease\n* Able to undergo MRI scans, tolerate neurosurgical procedure, blood draws and lumbar puncture.\n\nExclusion Criteria:\n\n* Are pregnant\n* Test positive for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B at Screening\n* Have an implanted deep brain stimulation device.","ALL","18 Years","65 Years",{"count":75,"type":76},21,"ESTIMATED","INTERVENTIONAL",[79,80],"PHASE1","PHASE2","The purpose of this research study is to determine whether an implantation of hNSC-01 is a safe and tolerable study intervention for Huntington's disease. This study is the first time that hNSC-01 is being tested in people.",[83],"Huntington Disease",[85,86,69],"Huntington's disease","stem cell","2026-04-06",{"date":89,"type":90},"2026-04-13","ACTUAL",{"date":87,"type":90},{"date":93,"type":76},"2031-01",{"name":57,"class":6},1]